Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 333

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure: The HIGH Randomized Clinical Trial

Open access
Azoulay, Elie, Lemiale, Virginie, Mokart, Djamel, Nseir, Saad, Argaud, Laurent, Pène, Frédéric, Kontar, Loay, Bruneel, Fabrice, Klouche, Kada, Barbier, François, Reignier, Jean, Berrahil-Meksen, Lilia, Louis, Guillaume, Constantin, Jean-Michel, Mayaux, Julien, Wallet, Florent, Kouatchet, Achille, Peigne, Vincent, Théodose, Igor, Perez, Pierre, Girault, Christophe, Jaber, Samir, Oziel, Johanna, Nyunga, Martine, Terzi, Nicolas, Bouadma, Lila, Lebert, Christine, Lautrette, Alexandre, Bigé, Naike, Raphalen, Jean-Herlé, Papazian, Laurent, Darmon, Michael, Chevret, Sylvie, Demoule, Alexandre · 2018 · JAMA

Abstract

Importance: High-flow nasal oxygen therapy is increasingly used for acute hypoxemic respiratory failure (AHRF). Objective: To determine whether high-flow oxygen therapy decreases mortality among immunocompromised patients with AHRF compared with standard oxygen therapy. Design, Setting, and Participants: The HIGH randomized clinical trial enrolled 776 adult immunocompromised patients with AHRF (Pao2 <60 mm Hg or Spo2 <90% on room air, or tachypnea >30/min or labored breathing or respiratory distress, and need for oxygen ≥6 L/min) at 32 intensive care units (ICUs) in France between May 19, 2016, and December 31, 2017. Interventions: Patients were randomized 1:1 to continuous high-flow oxygen therapy (n = 388) or to standard oxygen therapy (n = 388). Main Outcomes and Measures: The primary outcome was day-28 mortality. Secondary outcomes included intubation and mechanical ventilation by day 28, Pao2:Fio2 ratio over the 3 days after intubation, respiratory rate, ICU and hospital lengths of stay, ICU-acquired infections, and patient comfort and dyspnea. Results: Of 778 randomized patients (median age, 64 [IQR, 54-71] years; 259 [33.3%] women), 776 (99.7%) completed the trial. At randomization, median respiratory rate was 33/min (IQR, 28-39) vs 32 (IQR, 27-38) and Pao2:Fio2 was 136 (IQR, 96-187) vs 128 (IQR, 92-164) in the intervention and control groups, respectively. Median SOFA score was 6 (IQR, 4-8) in both groups. Mortality on day 28 was not significantly different between groups (35.6% vs 36.1%; difference, -0.5% [95% CI, -7.3% to +6.3%]; hazard ratio, 0.98 [95% CI, 0.77 to 1.24]; P = .94). Intubation rate was not significantly different between groups (38.7% vs 43.8%; difference, -5.1% [95% CI, -12.3% to +2.0%]). Compared with controls, patients randomized to high-flow oxygen therapy had a higher Pao2:Fio2 (150 vs 119; difference, 19.5 [95% CI, 4.4 to 34.6]) and lower respiratory rate after 6 hours (25/min vs 26/min; difference, -1.8/min [95% CI, -3.2 to -0.2]). No significant difference was observed in ICU length of stay (8 vs 6 days; difference, 0.6 [95% CI, -1.0 to +2.2]), ICU-acquired infections (10.0% vs 10.6%; difference, -0.6% [95% CI, -4.6 to +4.1]), hospital length of stay (24 vs 27 days; difference, -2 days [95% CI, -7.3 to +3.3]), or patient comfort and dyspnea scores. Conclusions and Relevance: Among critically ill immunocompromised patients with acute respiratory failure, high-flow oxygen therapy did not significantly decrease day-28 mortality compared with standard oxygen therapy. Trial Registration: clinicaltrials.gov Identifier: NCT02739451.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2018.14282

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 333

Metadata

Authors
Azoulay, E., Lemiale, V., Mokart, D., Nseir, S., Argaud, L., Pène, F., Kontar, L., Bruneel, F., Klouche, K., Barbier, F., Reignier, J., Berrahil-Meksen, L., Louis, G., Constantin, J.-M., Mayaux, J., Wallet, F., Kouatchet, A., Peigne, V., Théodose, I., Perez, P., Girault, C., Jaber, S., Oziel, J., Nyunga, M., Terzi, N., Bouadma, L., Lebert, C., Lautrette, A., Bigé, N., Raphalen, J.-H., Papazian, L., Darmon, M., Chevret, S., & Demoule, A.
Venue
JAMA
Published
2018-11-27
Volume
320
Issue
20
Pages
2099
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2898161514
Cited by
333
References
33
FWCI
25.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure: The HIGH Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2018.14282
The paper
Azoulay, E., Lemiale, V., Mokart, D., Nseir, S., Argaud, L., Pène, F., Kontar, L., Bruneel, F., Klouche, K., Barbier, F., Reignier, J., Berrahil-Meksen, L., Louis, G., Constantin, J.-M., Mayaux, J., Wallet, F., Kouatchet, A., Peigne, V., Théodose, I., . . . Demoule, A. (2018). Effect of High-Flow Nasal Oxygen vs Standard Oxygen on 28-Day Mortality in Immunocompromised Patients With Acute Respiratory Failure: The HIGH Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2018.14282

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.